Texto: 
- bcva: 20/20 -2 ou   (low myope ou)

- color vision (pip): 10/14 od  11/14 os

- red desaturation: 90% od

- white light brightness: 75% od

- pupils: 4->3mm ou,    2+ apd od

- motility: fd & v ou

- visual fields: gross defect to confrontation 7-9 clock hours od; full os

- iop: 16 ou

- sle: normal anterior segment ou

- dfe: 
     lens/vitreous: clear ou 
     macula: +flr, flat and unremarkable ou
     a/v:
        normal caliber w/o nicking, tortuosity,                     
        attenuation, or sheathing ou
     periphery: 
        flat and unremarkable ou
     disc: 
        0.1 c/d ou w/o pallor/heme
        slightly increased fullness/elevation od, but      
        sharp disc margins/clearly-defined vessels
        single flat, hypopigmented lesion just inferior   
        to disc margin od (1/5 dd)
- trans-sphenoidal surgical debulking (uncomplicated)

- serology:
     bartonella
     lyme
     rpr/fta

- mri orbits
presumably new-onset, painless, diffuse r monocular field loss  w/ +apd and subtle abnormalities of r optic disc
large intrasellar and suprasellar mass lesion
pituitary macroadenoma - null cell (non-secreting)
-optic nerve disease:
     neuropathy: compressive/infiltrative,     
     inflammatory, ischemic, toxic
     optic nerve drusen

- retrobulbar optic neuritis 

- neuroretinitis (bartonella, syphilis, lyme)

-intracranial process:
     - mass (pit adenoma, meningioma, glioma,      
     craniopharygioma)
     - aneurysm (most likely ica)
     inflammation (sarcoid, ms)

- retinal dystrophy/degeneration:
     - fundus flavimaculatus
21 y.o. woman reservist, activated & deployed into iraq in march.

air evacuated to germany and then subsequently to wramc in mid july for dyspnea.

pulmonology evaluation made a diagnosis of asthma, and she was started on po steroid burst w/ taper, albuterol, advair and singulaire.  

r-sided visual loss (od) started shortly after initiating these asthma meds and remained stable over next 1-2 weeks.  she then reported “i can’t see person standing to my right”. 

she denied any sudden onset - but is unable to pinpoint the moment when her symptoms began nor recall what she was doing; no “falling curtain”.

- no central vision loss ou

- no vision changes os

- no floaters, photopsia or amaurosis 

- no headache, eye pain or photophobia 

- no gross neurologic symptoms (diplopia, dysarthria, weakness, parasthesias, confusion)

- pmh/psh: 
     recent asthma dx

- fh: 
     non-contributory

- social hx:
     no tobacco/rare etoh
     1 previous sexual partner 2 years ago

- meds:
     po prednisone taper (currently 20mg qd)
     albuterol
     singular
     advair
     ocp 

-allergies: 
     pcn
- 10-15% of all intracranial tumors
- normal volunteers had 10% incidence of asymptomatic adenomas by mri

- found in 1.5-27% of autopsy cases

patients present with either:
     hormonal abnormalities
     symptoms of compressive lesion: headache, field    
     defects or cranial nerve palsies (cavernous sinus  
     invasion) 

genetic association:
     men type 1: 
          30% of patients have pit adenoma
          triad with parathyroid and pancreatic islet           
          tumors
     gsp:
          gene that encodes alpha-subunit of     
          gtp-binding protein gs
          mutation leads to activation of camp
     present in:
          40% of gh-secretors
          10% of null cell (non-secretors)
          6% of acth-secretors

classification:
     based on size:
          macroadenoma > 1cm
          microadenoma < 1cm
     based on what the tumor secretes:
          prolactin, gonadotropin, gh, acth, tsh
          nothin’ (null cell)

surgery:
     for most non-prolactin secreting adenomas
     usually trans-sphenoidal:
          mortality <1%
          common complications: nasal septal            
          perforation, ant. pit insufficiency,  
          transient diabetes insipidus, csf leak
          carotid injury and vision loss are rare

     success measures clinically and radiographically
     normalization of hormones varies with type/size of   
     tumor
     normalization of visual fields = 16-53%
     improvement of visual fields = 26-70%

treatment of prolactinomas:
     medical (dopamine agonists)
     - prl secretion inhibited by dopamine secretion  
     from the hypothalamus

     - decreases tumor size      (70-90% of cases)
     - normalizes prl levels     (70-90% of cases)
     - restores ovulation/menses (70-90% of cases)
     - improves visual fields    (70-90% of cases)

     "reversible, therefore lifelong tx is rule"

drugs:
     bromocriptine (classic—used for decades)
     side effects: n/v, dizziness, postural    
     hypotension, ha’s

newer agents:
     lisuride
     pergolide
     cabergoline

new txs for non-prl adenomas:
     gh-secretors:
          somatostatin analogs: octreotide & lanreotide
          reduce gh levels in 90% of pts 
          achieve complete suppression in 50% of pts

radiation:
     usually reserved for residual dz or recurrence   
     after surgery
     average total dose = 45-50 gy
     control rates of 85-95% @ 10 years

3 types:
     standard
     stereotactic fractionated
     stereotactic radiosurgery (single dose / gamma     
     knife)

disadvantages:
      slower reversal of neurologic symptoms
      slower drop in hormonal levels
      hypopituitarism: 50% of pts will have at least     
      one pit hormone deficiency @ 5 yrs       lifelong   
      follow-up
secondary brain tumor:
      risk of 1.3-1.7% @ 10 yrs
      risk of 1.9-2.7% @ 20 yrs
      (relative risk of 9.3-16 x general population)
      radiation-induced optic neuropathy/retinopathy
      low risk: 0.7-2%

srs(stereotactic radiosurgery)
       quicker drop in hormone levels
       adverse cns effects in 28% of cases at 3 yrs    
       compared with 0% with fsrt3

       "not recommended !!"


Keywords by value: 
- ou: 0.08788411439118786
- -: 0.07420648340183136
- :: 0.06024919061783929
- %: 0.05312689321284668
- od: 0.0505342999238408
- pit: 0.03168112606757615
- 70-90: 0.03168112606757615
- @: 0.02665487874842201
- yrs: 0.02308878909298227
- null: 0.0230471658151356
- visual: 0.02064965885584858
- fields: 0.019857720002587745
- pts: 0.0189503624714403
- gh-secretors: 0.018796414550035178
- prl: 0.018796414550035178
- stereotactic: 0.018613388540764948
- (: 0.018482602803680866
- ): 0.018256827943197572
- cases: 0.01820987759476204
- adenomas: 0.018166388725066148
- dopamine: 0.017318488791911626
- disc: 0.016969025658912666
- optic: 0.016868682386374526
- vision: 0.016835752552285355
- trans-sphenoidal: 0.016453957644559463
- os: 0.01631752566288547
- flat: 0.01601979509870846
- bartonella: 0.015840563033788075
- advair: 0.0153647772100904
- asthma: 0.01509970318255138
- levels: 0.01504158376661818
- gh: 0.014976031886435912
- taper: 0.014647352398531311
- normalization: 0.014647352398531311
- slower: 0.014647352398531311
- lifelong: 0.014362637275664525
- =: 0.014343662314542113
- radiosurgery: 0.013683631452384068
- albuterol: 0.013498106128312362
- secretion: 0.013498106128312362
- risk: 0.013199175468482245
- hormonal: 0.013022320304614686
- 10: 0.012284111847961238
- !: 0.012205705694260516
- macroadenoma: 0.01202018037018881
- ,: 0.011544139254468545
- 1cm: 0.011341174546908353
- lyme: 0.011277522173454875
- meds: 0.011215715058586534
- drop: 0.011215715058586534
- effects: 0.010633000058587213
- loss: 0.010577672377264135
- po: 0.010412991026102712
- hormone: 0.010330973369753468
- w/o: 0.010291118075484485
- she: 0.010229365208759797
- nerve: 0.009847375671068144
- what: 0.009619303477105177
- &: 0.00959932161665703
- dose: 0.0095345693008802
- w/: 0.009453074177596197
- myope: 0.009398207275017589
- 10/14: 0.009398207275017589
- 11/14: 0.009398207275017589
- 4-: 0.009398207275017589
- 7-9: 0.009398207275017589
- lens/vitreous: 0.009398207275017589
- +flr: 0.009398207275017589
- a/v: 0.009398207275017589
- nicking: 0.009398207275017589
- sheathing: 0.009398207275017589
- c/d: 0.009398207275017589
- pallor/heme: 0.009398207275017589
- fullness/elevation: 0.009398207275017589
- margins/clearly-defined: 0.009398207275017589
- rpr/fta: 0.009398207275017589
- +apd: 0.009398207275017589
- compressive/infiltrative: 0.009398207275017589
- neuroretinitis: 0.009398207275017589
- dystrophy/degeneration: 0.009398207275017589
- flavimaculatus: 0.009398207275017589
- reservist: 0.009398207275017589
- singulaire: 0.009398207275017589
- curtain: 0.009398207275017589
- floaters: 0.009398207275017589
- photopsia: 0.009398207275017589
- amaurosis: 0.009398207275017589
- tobacco/rare: 0.009398207275017589
- -allergies: 0.009398207275017589
- pcn: 0.009398207275017589
- volunteers: 0.009398207275017589
- 1.5-27: 0.009398207275017589
- gsp: 0.009398207275017589
- alpha-subunit: 0.009398207275017589
- gtp-binding: 0.009398207275017589
- non-secretors: 0.009398207275017589
- acth-secretors: 0.009398207275017589
- secretes: 0.009398207275017589
- nothin: 0.009398207275017589
- non-prolactin: 0.009398207275017589
- type/size: 0.009398207275017589
- 16-53: 0.009398207275017589
- 26-70: 0.009398207275017589
- restores: 0.009398207275017589
- ovulation/menses: 0.009398207275017589
- classic—used: 0.009398207275017589
- lisuride: 0.009398207275017589
- pergolide: 0.009398207275017589
- cabergoline: 0.009398207275017589
- txs: 0.009398207275017589
- non-prl: 0.009398207275017589
- lanreotide: 0.009398207275017589
- fractionated: 0.009398207275017589
- 1.3-1.7: 0.009398207275017589
- 1.9-2.7: 0.009398207275017589
- 9.3-16: 0.009398207275017589
- neuropathy/retinopathy: 0.009398207275017589
- 0.7-2: 0.009398207275017589
- srs: 0.009398207275017589
- fsrt3: 0.009398207275017589
- field: 0.009349043976808495
- symptoms: 0.009081694997433429
- gross: 0.008679288476765988
- bcva: 0.008659244395955813
- brightness: 0.008659244395955813
- dfe: 0.008659244395955813
- monocular: 0.008659244395955813
- non-secreting: 0.008659244395955813
- -intracranial: 0.008659244395955813
- craniopharygioma: 0.008659244395955813
- encodes: 0.008659244395955813
- prolactinomas: 0.008659244395955813
- inhibited: 0.008659244395955813
- normalizes: 0.008659244395955813
- 45-50: 0.008659244395955813
- 85-95: 0.008659244395955813
- 90: 0.008588543030244035
- tumor: 0.0084956601348009
- r: 0.008275148168093403
- -2: 0.008226978822279732
- apd: 0.008226978822279732
- fd: 0.008226978822279732
- macula: 0.008226978822279732
- 1/5: 0.008226978822279732
- -optic: 0.008226978822279732
- activated: 0.008226978822279732
- r-sided: 0.008226978822279732
- pinpoint: 0.008226978822279732
- partner: 0.008226978822279732
- singular: 0.008226978822279732
- gs: 0.008226978822279732
- ant: 0.008226978822279732
- disadvantages: 0.008226978822279732
- radiation-induced: 0.008226978822279732
- quicker: 0.008226978822279732
- ’: 0.008168529018055828
- started: 0.008127019441409465
- confrontation: 0.007920281516894037
- moment: 0.007920281516894037
- 20mg: 0.007920281516894037
- ocp: 0.007920281516894037
- somatostatin: 0.007920281516894037
- analogs: 0.007920281516894037
- dd: 0.0076823886050452
- initiating: 0.0076823886050452
- pmh/psh: 0.0076823886050452
- agonists: 0.0076823886050452
- hypopituitarism: 0.0076823886050452
- adenoma: 0.007608729961206849
- neurologic: 0.007608729961206849
- clock: 0.007488015943217956
- drusen: 0.007488015943217956
- camp: 0.007488015943217956
- gonadotropin: 0.007488015943217956
- insipidus: 0.007488015943217956
- bromocriptine: 0.007488015943217956
- achieve: 0.007488015943217956
- single: 0.007385203178017978
- cell: 0.007382432979471705
- iop: 0.0073236761992656555
- hypopigmented: 0.0073236761992656555
- germany: 0.0073236761992656555
- pulmonology: 0.0073236761992656555
- parasthesias: 0.0073236761992656555
- activation: 0.0073236761992656555
- gy: 0.0073236761992656555
- desaturation: 0.007181318637832263
- retrobulbar: 0.007181318637832263
- palsies: 0.007181318637832263
- hormones: 0.007181318637832263
- octreotide: 0.007181318637832263
- serology: 0.007055750369541874
- intrasellar: 0.007055750369541874
- burst: 0.007055750369541874
- microadenoma: 0.007055750369541874
- n/v: 0.007055750369541874
- newer: 0.007055750369541874
- <: 0.00703212265991853
- based: 0.006948167083724862
- new-onset: 0.006943425725983425
- fh: 0.006943425725983425
- sexual: 0.006943425725983425
- acth: 0.006943425725983425
- 50: 0.006931765493910031
- tumors: 0.006843744899084223
- 20/20: 0.006841815726192034
- wramc: 0.006841815726192034
- improves: 0.006841815726192034
- “: 0.00680490600805791
- ”: 0.006766761946755617
- tortuosity: 0.006749053064156181
- iraq: 0.006749053064156181
- recall: 0.006749053064156181
- secreting: 0.006749053064156181
- abnormalities: 0.006692461879953553
- 0.1: 0.006663719687105502
- dz: 0.006663719687105502
- motility: 0.00658471332020388
- islet: 0.00658471332020388
- adverse: 0.00658471332020388
- prolactin: 0.006511160152307343
- 1: 0.0065031760169287
- then: 0.006483937907083347
- debulking: 0.006442355758770487
- autopsy: 0.006442355758770487
- hypothalamus: 0.006442355758770487
- no: 0.0064212250052522535
- my: 0.0063167874904801
- dysarthria: 0.0063167874904801
- postural: 0.006259146529637588
- headache: 0.00625796468564136
- 10-15: 0.006204462846921649
- decreases: 0.006204462846921649
- suppression: 0.006204462846921649
- pip: 0.006152447746527798
- triad: 0.006152447746527798
- size: 0.0061084773376946086
- presumably: 0.006102852847130258
- syphilis: 0.006102852847130258
- retinal: 0.006102852847130258
- evacuated: 0.006102852847130258
- gene: 0.006102852847130258
- reversible: 0.006102852847130258
- ha: 0.006055462908355382
- reserved: 0.006055462908355382
- >: 0.006053662078184572
- unremarkable: 0.006032124560089681
- 3mm: 0.006010090185094405
- deployed: 0.006010090185094405
- qd: 0.006010090185094405
- dx: 0.005966569935072811
- etoh: 0.005966569935072811
- varies: 0.005966569935072811
- orbits: 0.005924756808043726
- march: 0.005884521916804018
- july: 0.005884521916804018
- person: 0.005884521916804018
- reversal: 0.005884521916804018
- decades: 0.005845750441142105
- mutation: 0.005808339652430728
- neuritis: 0.005772197273245567
- parathyroid: 0.005772197273245567
- knife: 0.005737240106056879
- compressive: 0.005638761086727438
- tx: 0.005638761086727438
- neuropathy: 0.005607857529293267
- photophobia: 0.005607857529293267
- hypotension: 0.005577824611418324
- lesion: 0.005566807759063288
- success: 0.005548614617614364
- usually: 0.005532896063681789
- gamma: 0.005520183650575813
- confusion: 0.005465499967859873
- leak: 0.005465499967859873
- 0: 0.005465499967859873
- sle: 0.005439175220961824
- doing: 0.005413484867466023
- prednisone: 0.005388399049331488
- caliber: 0.005363889968068482
- years: 0.005350198586393353
- toxic: 0.0053399316995694866
- ica: 0.0053399316995694866
- agents: 0.0053399316995694866
- or: 0.005338607403857716
- diplopia: 0.005316500029293607
- social: 0.005316500029293607
- average: 0.005316500029293607
- rates: 0.005293572305177441
- fundus: 0.00527112730603263
- 1-2: 0.005227607056011036
- classification: 0.005206495513051356
- shortly: 0.0051857939289819514
- falling: 0.0051455590377422426
- men: 0.0051455590377422426
- reduce: 0.0051455590377422426
- uncomplicated: 0.0051259970562196455
- periphery: 0.005087918076899732
- leads: 0.005087918076899732
- low: 0.005066456402700212
- radiographically: 0.005033234394183793
- drugs: 0.005033234394183793
- v: 0.004998277226995103
- pupils: 0.004981219293789942
- genetic: 0.004981219293789942
- suprasellar: 0.004964430000646936
- remained: 0.004964430000646936
- mortality: 0.004964430000646936
- septal: 0.004964430000646936
- tsh: 0.004947901017133114
- sharp: 0.0049316243943924015
- transient: 0.0049316243943924015
- deficiency: 0.004915592542191399
- dizziness: 0.004884234455617525
- ms: 0.004868894650231491
- nor: 0.004868894650231491
- standing: 0.004853772438086549
- insufficiency: 0.0048388617323565485
- steroid: 0.004809651738552589
- red: 0.004753528355305871
- population: 0.004753528355305871
- patients: 0.004715510872848669
- perforation: 0.004687289782697121
- sarcoid: 0.004674521988404247
- protein: 0.004674521988404247
- 75: 0.004661905295816825
- 2+: 0.004661905295816825
- standard: 0.004661905295816825
- cns: 0.004661905295816825
- types: 0.004649436170269712
- next: 0.004624927089006707
- began: 0.004612880654834071
- painless: 0.004577537150231831
- pituitary: 0.004566011653319021
- least: 0.004566011653319021
- residual: 0.0045211166795982045
- hx: 0.004510182244451946
- nasal: 0.004510182244451946
- diabetes: 0.004510182244451946
- /: 0.004499358820716321
- ``: 0.004477899867018799
- pancreatic: 0.004457131594602199
- color: 0.0044468310499201765
- ischemic: 0.0044366290765554105
- denied: 0.0044366290765554105
- association: 0.004426523805814959
- surgery: 0.004424305041279904
- '': 0.0043917899829045695
- invasion: 0.00438703417715787
- relative: 0.004339644238382994
- ;: 0.004318595284547108
- dyspnea: 0.004312189551706645
- therefore: 0.00430319289003728
- 28: 0.004294271515122018
- margin: 0.004285424177366479
- normal: 0.004284474801489662
- 3: 0.004266472338393475
- light: 0.004250751265100423
- improvement: 0.004250751265100423
- cavernous: 0.0042254671215851605
- t: 0.004217170596593631
- sudden: 0.004208938138071339
- unable: 0.004208938138071339
- most: 0.004206471517543872
- mri: 0.004186089242888315
- subtle: 0.004184615453885655
- defects: 0.004184615453885655
- incidence: 0.0041766296631296235
- control: 0.004153025051320227
- subsequently: 0.0041299317711697165
- 16: 0.004122343852439584
- 21: 0.004122343852439584
- present: 0.0041151572578500654
- glioma: 0.004107328138279948
- carotid: 0.004085193819038552
- in: 0.004043257005610122
- clinically: 0.003994258232138877
- segment: 0.003974330585004386
- recurrence: 0.003974330585004386
- either: 0.003967769960724665
- cranial: 0.003961249462838272
- have: 0.0039454969687955045
- full: 0.0039355591093424725
- total: 0.003922942416755049
- measures: 0.0038981483206310973
- for: 0.0038865039906328096
- but: 0.00388593454378153
- inflammation: 0.0038739177757722955
- compared: 0.003856099565778969
- intracranial: 0.0038502257322917937
- general: 0.003838574271170056
- 40: 0.0038327959476419757
- eye: 0.0038213324169636582
- mid: 0.003809990841052085
- just: 0.0038043649806034246
- csf: 0.0038043649806034246
- rule: 0.0038043649806034246
- recommended: 0.0037766725643952575
- after: 0.00376972537869766
- i: 0.0037657939181540614
- stable: 0.0037550251591066163
- of: 0.003726134353880227
- slightly: 0.003682543985348692
- vessels: 0.003667633279618692
- attenuation: 0.0036627090303049453
- made: 0.0036288618039567785
- currently: 0.00360999231877618
- complications: 0.00360999231877618
- aneurysm: 0.0036006813593212183
- hours: 0.0035822999025680135
- previous: 0.003537686778969399
- rare: 0.003537686778969399
- process: 0.0035075324998237894
- meningioma: 0.0035032935356663912
- 30: 0.0035032935356663912
- defect: 0.0034101783862472567
- ago: 0.0033909688921079408
- weakness: 0.0033833809733778085
- clear: 0.003368365259218172
- non-contributory: 0.00336464414520989
- sinus: 0.003331725980429038
- reported: 0.0033209753204432963
- 20: 0.0032756025971823195
- complete: 0.003206157712138651
- to: 0.0031870754361416885
- new: 0.0031746140477617894
- inflammatory: 0.0031591854415693216
- side: 0.0031561263345032736
- inferior: 0.0030909556091248003
- air: 0.003082369537901883
- asymptomatic: 0.0030795228123625664
- type: 0.0030710279619903095
- recent: 0.00306260026528763
- by: 0.0030338398789869396
- white: 0.0030214330625927695
- x: 0.0030054012103917665
- central: 0.002997474794093773
- radiation: 0.0029896068758660304
- follow-up: 0.0029637921017502578
- injury: 0.0029042734988153516
- onset: 0.0028757155926707354
- found: 0.0028710294397144053
- any: 0.002868694065109055
- will: 0.0028501929833466334
- medical: 0.002803102132266529
- diffuse: 0.0027580036464555594
- brain: 0.0027413129246298103
- her: 0.0027392448384700803
- 6: 0.0027208104065830217
- see: 0.002718781675083996
- 5: 0.002665416228618511
- evaluation: 0.0026463100168729295
- y.o: 0.0026294023801563967
- s: 0.0026127587069451888
- changes: 0.002610925347798572
- when: 0.0026090951360511786
- weeks: 0.0025855839625811817
- all: 0.00257667749406321
- likely: 0.00256960550739409
- secondary: 0.0025469402628025667
- mass: 0.002534031997756001
- one: 0.0024687967839132664
- at: 0.002468578151026936
- common: 0.002384080183322385
- these: 0.0023708365585904476
- anterior: 0.0023462610061436434
- over: 0.0023194483903411114
- on: 0.002315216457458725
- increased: 0.0022286618142853473
- into: 0.0021677253389762335
- and: 0.0021109798113586385
- was: 0.0021072015399012513
- woman: 0.002104374144444463
- diagnosis: 0.002091918263092132
- can: 0.00206633513056404
- large: 0.0019920495008860124
- had: 0.0019657247539879618
- 2: 0.0019617318726125226
- surgical: 0.0019149485823576264
- treatment: 0.001843941321536127
- that: 0.0015735402223441613
- disease: 0.0014890592123834798
- from: 0.0013501446835332753
- not: 0.001316437816356008
- are: 0.0012418698001381682
- is: 0.0011989142396262805
- pain: 0.0011125886647449198
- right: 0.0009612278348725124
- with: 0.0006236896380058089
- the: 0.0004421618913762019
- a: 0.00042281428765309306
- .: 0.0003027678984848296
